Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 324

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 324
---
                                |     670,345 |   |     | $    |            — |   |
| Supplemental disclosure of noncash activities:                                       |     |                                  |             |   |     |      |              |   |
| Accretion of Class A common stock subject to possible redemption                     |     | $                                |     606,346 |   |     | $    |    2,662,553 |   |
| Shareholder redemption liability                                                     |     | $                                |           — |   |     | $    |   27,842,747 |   |
| Conversion of Class B common to Class A common                                       |     | $                                |        (459 | ) |     | $    |            — |   |
| Excise tax liability accrued for Class A common stock redemptions                    |     | $                                |      56,389 |   |     | $    |            — |   |

The accompanying notes are an integral part of the financial statements. F-30 PHOENIX BIOTECH ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2023 Note 1 — Description of Organization and Business Operations and Liquidity Phoenix Biotech Acquisition Corp. (the “Company”) was incorporated in Delaware on June 8, 2021. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses (a “business combination”). The Company is not limited to a particular industry or geographic region for purposes of consummating a business combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. As of December 31, 2023, the Company had not commenced any operations. All activity through December 31, 2023 relates to the Company’s formation and initial public offering (“IPO”), which is described below and, since the offering, the search for a prospective initial business combination. The Company will not generate any operating revenues until after the completion of its initial business combination, at the earliest. The Company generates non-operating income in the form of interest income earned on investments from the proceeds derived from the IPO and placed in the Trust Account (defined below). The registration statement for the Company’s IPO was declared effective on October 5, 2021. On October 8